MX2024007649A - Paradigma de tratamiento para una terapia con anticuerpos anti cumulo de diferenciacion (anti-cd19). - Google Patents
Paradigma de tratamiento para una terapia con anticuerpos anti cumulo de diferenciacion (anti-cd19).Info
- Publication number
- MX2024007649A MX2024007649A MX2024007649A MX2024007649A MX2024007649A MX 2024007649 A MX2024007649 A MX 2024007649A MX 2024007649 A MX2024007649 A MX 2024007649A MX 2024007649 A MX2024007649 A MX 2024007649A MX 2024007649 A MX2024007649 A MX 2024007649A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody therapy
- treatment paradigm
- treatment
- antibody
- paradigm
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21216714 | 2021-12-22 | ||
| PCT/EP2022/087393 WO2023118395A1 (en) | 2021-12-22 | 2022-12-22 | Treatment paradigm for an anti-cd19 antibody therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007649A true MX2024007649A (es) | 2024-08-26 |
Family
ID=79018498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007649A MX2024007649A (es) | 2021-12-22 | 2022-12-22 | Paradigma de tratamiento para una terapia con anticuerpos anti cumulo de diferenciacion (anti-cd19). |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230357392A1 (https=) |
| EP (1) | EP4453033A1 (https=) |
| JP (1) | JP2025500411A (https=) |
| KR (1) | KR20240131370A (https=) |
| CN (1) | CN119013293A (https=) |
| AU (1) | AU2022419233A1 (https=) |
| CA (1) | CA3255552A1 (https=) |
| CL (2) | CL2024001870A1 (https=) |
| IL (1) | IL313736A (https=) |
| MX (1) | MX2024007649A (https=) |
| TW (1) | TW202334231A (https=) |
| WO (1) | WO2023118395A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| US12358983B2 (en) | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| PL2383297T3 (pl) | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| KR101490468B1 (ko) * | 2010-02-04 | 2015-02-06 | 삼성전자 주식회사 | 데이터 처리 장치 및 방법 |
| HRP20220224T1 (hr) * | 2011-08-16 | 2022-04-29 | Morphosys Ag | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom |
| KR20140064873A (ko) * | 2011-08-16 | 2014-05-28 | 모르포시스 아게 | 항-cd19 항체 및 질소 머스타드를 사용한 조합 요법 |
| AU2015277516A1 (en) * | 2014-06-16 | 2016-12-22 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (CLL) |
| RU2767063C2 (ru) * | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| TW202525340A (zh) * | 2019-10-31 | 2025-07-01 | 美商英塞特公司 | 用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合 |
| WO2022117799A2 (en) * | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
-
2022
- 2022-12-22 CA CA3255552A patent/CA3255552A1/en active Pending
- 2022-12-22 KR KR1020247024443A patent/KR20240131370A/ko active Pending
- 2022-12-22 US US18/087,068 patent/US20230357392A1/en not_active Abandoned
- 2022-12-22 WO PCT/EP2022/087393 patent/WO2023118395A1/en not_active Ceased
- 2022-12-22 AU AU2022419233A patent/AU2022419233A1/en active Pending
- 2022-12-22 EP EP22844057.4A patent/EP4453033A1/en active Pending
- 2022-12-22 MX MX2024007649A patent/MX2024007649A/es unknown
- 2022-12-22 JP JP2024537895A patent/JP2025500411A/ja active Pending
- 2022-12-22 IL IL313736A patent/IL313736A/en unknown
- 2022-12-22 TW TW111149579A patent/TW202334231A/zh unknown
- 2022-12-22 CN CN202280090874.3A patent/CN119013293A/zh active Pending
-
2024
- 2024-06-19 CL CL2024001870A patent/CL2024001870A1/es unknown
-
2025
- 2025-02-26 CL CL2025000520A patent/CL2025000520A1/es unknown
- 2025-08-19 US US19/303,673 patent/US20260062483A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025500411A (ja) | 2025-01-09 |
| AU2022419233A1 (en) | 2024-07-04 |
| TW202334231A (zh) | 2023-09-01 |
| KR20240131370A (ko) | 2024-08-30 |
| WO2023118395A1 (en) | 2023-06-29 |
| CN119013293A (zh) | 2024-11-22 |
| CA3255552A1 (en) | 2023-06-29 |
| CL2025000520A1 (es) | 2025-06-23 |
| IL313736A (en) | 2024-08-01 |
| US20230357392A1 (en) | 2023-11-09 |
| US20260062483A1 (en) | 2026-03-05 |
| CL2024001870A1 (es) | 2024-12-13 |
| EP4453033A1 (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007649A (es) | Paradigma de tratamiento para una terapia con anticuerpos anti cumulo de diferenciacion (anti-cd19). | |
| JOP20200292A1 (ar) | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان | |
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| NZ601580A (en) | Therapeutic methods using anti-cd200 antibodies | |
| MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| RU2012135430A (ru) | Новые радиоиммуноконъюгаты и их применения | |
| CY1113287T1 (el) | Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα | |
| MX2020006171A (es) | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. | |
| MX2020009842A (es) | Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido. | |
| BR112019023909A2 (pt) | método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio. | |
| Einstein et al. | Phase II trial of adjuvant pelvic radiation “sandwiched” between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma | |
| Okano | Immunotherapy for head and neck cancer: Fundamentals and therapeutic development | |
| EA201792294A1 (ru) | Комбинированное лечение (варианты) с применением серибантумаба | |
| WO2022238963A3 (en) | Genetically engineered immune cells targeting cd70 for use in treating solid tumors | |
| ZA201907754B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
| MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
| MX2021005266A (es) | Regimen de dosificacion del anticuerpo anti-gen de activacion de linfocitos 3 (anti-lag3) y terapia combinada con anticuerpo anti-muerte progamada-1 (anti-pd-1) para el tratamiento del cancer. | |
| RU2013154048A (ru) | Композиции и способы лечения рака | |
| MX2023009376A (es) | Uso de conjugado de anticuerpo-farmaco dirigido a her2 en el tratamiento de cancer de mama especifico. | |
| MX2015006931A (es) | Terapia combinada para tratar cánceres her2-positivos. | |
| MX2024007749A (es) | Formulaciones clinicas de anticuerpos anti-tigit. | |
| Wobb et al. | Comparison of chronic toxicities between brachytherapy-based accelerated partial breast irradiation and whole breast irradiation using intensity modulated radiotherapy | |
| CR20220149A (es) | Dosis para anticuerpos anti-triptasa | |
| MX2023006404A (es) | Terapia combinada de anticuerpos y taxanos. | |
| Lee et al. | Subtype-specific radiation response and therapeutic effect of FAS death receptor modulation in human breast cancer |